BridgeMD
A Phase 1/2a gene therapy clinical trial in Retinitis Pigmentosa subjects.
EU CTIS ID: 2024-516059-42-00
What this study is testing
To evaluate the safety and tolerability of escalating doses of GS030-DP administered via a single intravitreal injection (IVT) and repeated light stimulation using GS030-MD in subjects with non-syndromic retinitis pigmentosa.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Signed informed consent form.
- Ability to wear, utilize, and follow all instructions on proper use of the GS030-MD.
- Interpupillary distance of ≥51 mm and ≤72 mm.
- Refractive error of the study eye between -9 diopters and +6 diopters.
- Review of all selection criteria to ensure continued compliance from Visit 2 through Visit 4.
- Have a negative urine pregnancy test at Visit 4 for women of childbearing potential (women who are 2 years post-menopausal or surgically sterile are not considered to be of childbearing potential).
You likely can't join if
- Prior receipt of any gene therapy.
- Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
- Subjects who are human immunodeficiency virus (HIV) positive.
- Subjects with known allergy to corticosteroids, or who will be unable to tolerate the corticosteroid regimen, or with an active intercurrent infection contraindicating treatment.
- Subjects who have undergone significant ocular surgery (per investigator determination) within 3 months prior to Visit 1.
- Presence of narrow iridocorneal angles contraindicating pupillary dilation.
See the full eligibility criteria
Who can join
- Signed informed consent form.
- Ability to wear, utilize, and follow all instructions on proper use of the GS030-MD.
- Interpupillary distance of ≥51 mm and ≤72 mm.
- Refractive error of the study eye between -9 diopters and +6 diopters.
- Review of all selection criteria to ensure continued compliance from Visit 2 through Visit 4.
- Have a negative urine pregnancy test at Visit 4 for women of childbearing potential (women who are 2 years post-menopausal or surgically sterile are not considered to be of childbearing potential).
- Have a negative test result for infection with HIV (results from test performed at Visit 1).
- Ability to tolerate repeated light stimuli produced by the GS030-MD, as assessed in the inclusion phase (Visit 2 through Visit 4).
- Age ≥18 years to ≤75 years at the time of ICF signature.
- Diagnosis of non-syndromic RP defined as: Clinical diagnosis of nonsyndromic RP based on history, mid-peripheral visual dysfunction, and fundoscopic appearance, or diagnosis of non-syndromic RP is confirmed on full-field ERG.
- Visual acuity: Visual acuity in the dose-escalation cohorts of no better than LP, or Visual acuity in the extension cohort of no better than CF pending review of dose-escalation cohort data by the DSMB.
- Relatively preserved ganglion cell layer volume and retinal nerve fiber layer thickness, as measured with spectral domain optical coherence tomography (SD-OCT).
- Retains memory of former useful vision.
- Ability to obtain adequate pupillary dilation to permit thorough ocular examination and testing.
- Negative serum pregnancy test for women of childbearing age only.
- Female subjects (if of childbearing potential) must agree to use highly effective methods of birth control up to 12 months after GS030-DP IVT, and male subjects must agree to use condoms for up to 12 months after GS030-DP IVT. (Highly effective methods of birth control include: combined (estrogen and progesterone containing) hormonal contraception (oral, injectable or transdermal) associated with inhibition of ovulation; progesterone-only hormonal contraception (oral, injectable or transdermal) associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner (provided that partner is the sole sexual partner of the woman of childbearing potential and that the vasectomized partner has received medical assessment of the surgical success); true sexual abstinence, when consistent with the preferred and usual lifestyle of the subject (sexual abstinence defined as refraining from heterosexual intercourse during the entire period of risk associated with study treatments).
What rules you out
- Prior receipt of any gene therapy.
- Subjects with any condition that would not allow them to complete follow-up examinations during the study and, in the opinion of the investigator, would make them unsuitable for the study.
- Subjects who are human immunodeficiency virus (HIV) positive.
- Subjects with known allergy to corticosteroids, or who will be unable to tolerate the corticosteroid regimen, or with an active intercurrent infection contraindicating treatment.
- Subjects who have undergone significant ocular surgery (per investigator determination) within 3 months prior to Visit 1.
- Presence of narrow iridocorneal angles contraindicating pupillary dilation.
- Presence of disorders of the ocular media which interfere with visual acuity and other ocular assessments, including SD-OCT, during the study period.
- Presence of any systemic or ocular diseases, or pathologies, other than non-syndromic RP, or their associated therapies, that can cause or have the potential to cause vision loss.
- Prior vitreomacular surgery.
- Presence of vitreo-macular adhesion or traction, epiretinal membrane macular pucker and macular hole, evident by ophthalmoscopy and/or by SD-OCT examinations and assessed by the investigator to significantly affect central vision.
- Current evidence of retinal detachment assessed by the investigator to significantly affect central vision.
- Subjects participating in another clinical trial and receiving an investigational medicinal product within 90 days prior to Visit 1.
- Active ocular inflammation or recurrent history of idiopathic or autoimmune-associated uveitis.
- Hypersensitivity to GS030-DP or to any of the ingredients.
- Presence of an Active Implantable Medical Device.
- Subjects who have undergone thermal laser procedure to the retina within 3 months of trial entry, or any prior thermal laser procedure to the macular region.
- Any non-selection criteria which become applicable after the selection visit.
- Presence, at the time of study inclusion, of infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
- Presence of systemic illness, including alcohol and drug abuse (except nicotine), or medically significant abnormal laboratory values that are deemed by the investigator to preclude the subject's safe participation in the study.
- Presence of illness or disease that, in the opinion of the investigator, include symptoms and/or associated treatments that can alter visual function, for instance cancers or pathology of the central nervous system.
- Any medical or psychological condition that, in the opinion of the investigator, may compromise the safe participation of the subject in the study or would preclude compliance with the study protocol or ability of the subject to successfully complete the study.
- The subject is unable or unwilling to comply with the protocol requirements.
- Subjects with systemic disease or other pathology other than that related to diagnosis of non-syndromic RP whose symptoms or associated treatments may affect vision, for example cancers or pathology of the central nervous system.
- Failure to demonstrate presence of either ganglion cell layer or recognizable retinal nerve fiber layer.
- Subjects with systemic disease or other medical or psychiatric conditions that preclude safe participation in the study.
- Subjects who are taking photosensitizing drugs used in psoralen plus ultraviolet light (PUVA) therapy for psoriasis, eczema, vitiligo, and other similar diseases, or photosensitizing drugs used for photodynamic therapy in the treatment of cancer or eye diseases.
- Subjects receiving immunosuppressive therapies, other than the immune modulating regimen described in this protocol.
- Subjects of reproductive potential unwilling to use effective contraception for the 12 months after administration of GS030-DP.
- Subjects who are pregnant or breastfeeding.
- Subjects who are unwilling or unable to comply with the study protocol.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.